

FORM 5A

ANNUAL LISTING SUMMARY

Listed Issuer Name: Restart Life Sciences Corp.

Website: <http://restartlife.co>

Listing Statement Date: April 24, 2026

Description(s) of listed securities(symbol/type): HEAL

Brief Description of the Issuer's Business: Restart Life Science Corp. is a Canadian-based life sciences company listed on the CSE, with a focus on the development, acquisition, and commercialization of products and brands primarily related to cognitive health, brain wellness, memory, and functional nutrition. For more information about Restart Life, please visit the Company's website at www.restartlife.co

Description of additional (unlisted) securities outstanding

Jurisdiction of Incorporation: British Columbia

Fiscal Year End: December 31

Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): February 7, 2025

Financial Information as at: December 31, 2025, unless otherwise provided.

	Current	Previous N/A
Cash	1,599,049	
Current Assets	\$160,937	
Non-current Assets	\$7,222	
Current Liabilities	\$480,206	
Non-current Liabilities	\$-	
Shareholders' equity	\$1,287,002	
Revenue	-	
Net Income (loss)	(\$1,390,538)	
Net Cash Flow (used in) Operations	(\$717,219)	

SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in the Schedules. If the required details are included in Schedule A or B, provide specific reference to the page or note.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

N/A. See the Issuer's Annual Form 5A dated April 8, 2025.

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

2. Summary of securities issued and options granted during the period.

Provide the following information for the Listed Issuer's fiscal year:

N/A. See the Issuer's Annual Form 5A dated April 8, 2025.

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

N/A. See the Issuer's Annual Form 5A dated April 8, 2025.

- (a) description of authorized share capital including number of securities outstanding for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
- (b) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
- (c) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

4. List the names of the directors and officers and include the position(s) held and the date of appointment, as at the date this report is signed and filed.

Steve Loutskou, CEO, President, and Director
Dr. Georg Hochwimmer, Director
Khavita Harrycharran, Director
Rebecca Hudson, CFO
Kelly Pladson, Corporate Secretary

5. Financial Resources

- a) State the business objectives that the Issuer expects to accomplish in the forthcoming 12-month period;

Over the next 12 months, the Issuer intends to advance its business as a life sciences company, with a focus on the development, acquisition, and commercialization of products and brands primarily related to cognitive health, brain wellness, memory, and functional nutrition. The business objectives the Company is proposing to accomplish over the next 12 months, and the anticipated time period for completion and estimated cost are described in the following table:

Business Objective	Milestone that must occur for Business Objective to be Accomplished	Timing	Estimated Cost
Acquire Holy Crap Foods Inc.	Complete due diligence and enter into definitive agreement with Belly Food Group Inc.	Q1	\$900,000
Food studies and research (i) to generate data to support product development, validation and refinement; and (ii) develop new health and wellness products, with an emphasis on cognitive health and brain function	Food study in relation to BrainQ	Q1-Q4	\$35,000
	Advance initial phase of food studies with a Canadian accredited research institution	Q1-Q2	\$50,000
	Include selected Holy Crap products within scope of studies	Q1-Q2	
	Determine advancement of subsequent phases based on initial results	Q3-Q4	\$15,000
Transition and integration of Holy Crap into Issuer's operational and brand ecosystem	Complete operational planning and manufacturing coordination	Q1	\$25,000
Achieve efficiencies in production and operational management	Facility upgrades and improvements	Q1-Q2	\$50,000
	Integrate existing brands (BrainQ and BrainBalls) into Holy Crap manufacturing and operational facility	Q2-Q4	\$100,000
	Consolidate supply chain and inventory management	Q2-Q4	\$10,000
Continue joint venture with BrainBalls		Q1-Q4 (ongoing)	\$25,000

Business Objective	Milestone that must occur for Business Objective to be Accomplished	Timing	Estimated Cost
Operate Holy Crap as a subsidiary	Maintain ongoing production and distribution	Q1-Q4 (ongoing)	\$25,000
Evaluate health and wellness product opportunities, including nutraceuticals and other products related to cognitive health, memory, aging, and wellness applications		Q1-Q4 (ongoing)	\$50,000
General working capital			\$128,585
		TOTAL:	\$1,413,585

- b) Describe each significant event or milestone that must occur for the business objectives in (a) to be accomplished and state the specific time period in which each event is expected to occur and the costs related to each event;

See paragraph (a) above.

- c) Disclose the total funds available to the Issuer and the following breakdown of those funds:
- (i) the estimated consolidated working capital (deficiency) as of the most recent month end prior to filing the Listing Statement, and
The consolidated working capital as at December 31, 2025 was \$1,313,585.
 - (ii) the total other funds, and the sources of such funds, available to be used to achieve the objectives and milestones set out in paragraphs (a) and (b); and
The Issuer expects to generate approximately \$100,000 in net profits from Holy Crap operations during fiscal 2026.
 - (iii) describe in reasonable detail and, if appropriate, using tabular form, each of the principal purposes, with approximate amounts, for which the funds available described under the preceding paragraph will be used by the Issuer.

See paragraph (a) above.

6. Status of Operations

During the fiscal year, did the Listed Issuer

- (a) reduce or impair its principal operating assets; or **No.**
- (b) cease or substantively reduce its business operations with respect to its stated business objectives in the most recent Listing Statement? **No.**

Provide details:

7. Business Activity

a) Activity for a mining or oil and gas Listed Issuer

- (i) For the most recent fiscal year, did the Listed Issuer have positive cash flow, significant revenue from operations, or \$50,000 in exploration or development expenditures? **N/A**

Provide details.

- (ii) If the response to (i) above is “no”, for the three most recent fiscal years did the Listed Issuer have an aggregate of \$100,000 in exploration or development expenditures? **N/A**

Provide details.

b) Activity for industry segments other than mining or oil & gas

- (i) For the most recent fiscal year, did the Listed Issuer have positive cash flow, or \$100,000 in revenue from operations or \$100,000 in development expenditures? **No.**

Provide details.

- (ii) If the response to (i) above is “no”, for the three most recent fiscal years, did the Listed Issuer have either \$200,000 in operating revenues or \$200,000 in expenditures directly related to the development of the business? **No.**

Provide details.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Annual Listing Summary.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5A Annual Listing Statement is true.

Dated April 24, 2026.

Steve Loutskou
Name of Director or Senior Officer

/s/ Steve Loutskou
Signature

President & CEO
Official Capacity

Issuer Details Name of Issuer Restart Life Sciences Corp	For Year Ended N/A	Date of Report YY/MM/D 26/04/24
Issuer Address 700-838 W Hastings Street		
City/Province/Postal Code Vancouver, BC, V6C 0A6	Issuer Fax No. ()	Issuer Telephone No. (778) 819-0244
Contact Name Kelly Pladson	Contact Position Corporate Secretary	Contact Telephone No. (604) 726-6749
Contact Email Address kelly@niacorporateservices.com	Web Site Address https://restartlife.co/	